Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia
- 27 August 1981
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 305 (9), 478-482
- https://doi.org/10.1056/nejm198108273050902
Abstract
We studied the effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum levels of lipoproteins and ubiquinone-10 in seven heterozygous patients with familial hypercholesterolemia. ML-236B was given at doses of 30 to 60 mg per day for 24 weeks. Serum cholesterol decreased from 390±9 to 303±8 mg per deciliter (10.1 ±0.2 to 7.88±0.2 mmol per liter, mean ±S.E.M.; Pμg per milliliter (P<0.05). No adverse effects were observed. We conclude that ML-236B is effective in lowering serum cholesterol without lowering serum ubiquinone-10 in heterozygous patients with familial hypercholesterolemia. (N Engl J Med. 1981; 305:478–82.)This publication has 40 references indexed in Scilit:
- Cholestyramine Promotes Receptor-Mediated Low-Density-Lipoprotein CatabolismNew England Journal of Medicine, 1980
- Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductaseAtherosclerosis, 1979
- Plasma High-Density LipoproteinsNew England Journal of Medicine, 1978
- Inhibitory Effects on Lipid Metabolismn in Cultured Cells of ML‐236B, a Potent Inhibitor of 3‐Hydroxt‐3‐methylglutaryl‐Cornzyme‐A ReductaseEuropean Journal of Biochemistry, 1978
- Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by achilles' tendon thicknessAtherosclerosis, 1977
- Inhibition of Cholesterol Synthesis in vitro and in vivo by ML‐236A and ML‐236B, Competitive Inhibitors of 3‐Hydroxy‐3‐methylglutaryl‐Coenzyme A ReductaseEuropean Journal of Biochemistry, 1977
- Effect of hypertonic mannitol and isoproterenol on regional coronary flow following right ventriculotomy.Cell Metabolism, 1976
- Differences among Hyperlipoproteinaemic Subjects in the Response of Lipoprotein Lipids to Resin TherapyEuropean Journal of Clinical Investigation, 1975
- Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemiaJAMA, 1972
- Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemiaAtherosclerosis, 1972